Nebivolol offers a unique pharmacological profile among beta-blockers due to its nitric oxide-induced vasodilation and preservation of heart rate response to exercise.
May inform beta-blocker choice when vasodilation and exercise heart-rate preservation are priorities; leaves open effects on clinical outcomes.
beta-blockers have been widely used for the treatment of hypertension, congestive heart failure and angina, as well as in the post-myocardial infarction population. Both beta(1) selective and nonselective agents are available. Nebivolol is a new highly beta(1 )selective antagonist with a nonadrenergic, nitric oxide potentiating vasodilatory property, which is unique among beta-blockers. In addition, nebviolol does not inhibit the increase in the heart rate response to exercise, which is unique among beta-blockers. Nebviolol has been tested successfully in double-blind, placebo-controlled trials in both hypertension and congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Robert Weiss (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: